A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease


Disclosures: JM, NS, DE are employed or were employed by Imara which is developing IMR-687 CC, AF, CC, JN, PN, FA, GV, OH, JAR, JB, TM received financial support from Imara through a sponsored research agreement(s)

Contributions: JM initiated and directed the program and wrote the paper NS/AP lead the chemistry & biochemistry program DE lead the toxicology program CC, AF, OH, TM performed/directed cell and animal studies CC, JN, PN, FA, GV, JAR, JB performed/directed animal studies